Cellectis (NASDAQ:CLLS – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Cellectis to related companies based on the strength of its analyst recommendations, profitability, valuation, risk, dividends, institutional ownership and earnings.
Valuation and Earnings
This table compares Cellectis and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cellectis | $56.58 million | -$67.59 million | -1.70 |
| Cellectis Competitors | $722.78 million | $12.25 million | -9.92 |
Cellectis’ competitors have higher revenue and earnings than Cellectis. Cellectis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Cellectis has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500. Comparatively, Cellectis’ competitors have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Cellectis and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectis | 2 | 2 | 2 | 1 | 2.29 |
| Cellectis Competitors | 9774 | 15037 | 45265 | 1571 | 2.54 |
Cellectis currently has a consensus price target of $5.46, indicating a potential upside of 394.12%. As a group, “Biotechnology” companies have a potential upside of 98.97%. Given Cellectis’ higher possible upside, analysts plainly believe Cellectis is more favorable than its competitors.
Insider and Institutional Ownership
63.9% of Cellectis shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Cellectis and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectis | -102.34% | -94.19% | -21.34% |
| Cellectis Competitors | -9,054.29% | -198.66% | -30.54% |
Summary
Cellectis beats its competitors on 9 of the 13 factors compared.
Cellectis Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
